Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 in Relapsed or Refractory B-Cell Malignancies
NCT00275431Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Nov 2005
- Primary completion
- Dec 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of r-(-)-gossypol acetic acid in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and 2 more, sponsored by Ascenta Therapeutics. Primary endpoint: Objective Response Rate. Started Nov 2005; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00275431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275431.